NM_000156.6:c.189G>C
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP7BP4
This summary comes from the ClinGen Evidence Repository: The NM_000156.6:c.189G>C (p.Arg63=) variant in GAMT is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by phyloP (score -1.308) (BP4, BP7). To our knowledge, this variant has not been reported among individuals with GAMT deficiency and results of functional studies are unavailable. The highest population minor allele frequency in gnomAD v4.1.0 is 0.0004955 (3/6054) in the Middle Eastern population. This is higher than the ClinGen CCDS VCEP's threshold for PM2_Supporting (<0.0004), and lower than the threshold for BS1 (>0.001). Therefore, no population criteria are met. There is a ClinVar entry for this variant (Variation ID: 288963). In summary, this variant meets the criteria to be classified as likely benign for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): BP4, BP7.(Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on May 20, 2025). LINK:https://erepo.genome.network/evrepo/ui/classification/CA9043767/MONDO:0012999/026
Frequency
Consequence
NM_000156.6 synonymous
Scores
Clinical Significance
Conservation
Publications
- guanidinoacetate methyltransferase deficiencyInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152232Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000213 AC: 5AN: 235050 AF XY: 0.0000235 show subpopulations
GnomAD4 exome AF: 0.0000220 AC: 32AN: 1454706Hom.: 0 Cov.: 33 AF XY: 0.0000304 AC XY: 22AN XY: 723122 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152350Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74510 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:1
GAMT: BP4, BP7 -
- -
Deficiency of guanidinoacetate methyltransferase Uncertain:1Benign:1
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. -
The NM_000156.6:c.189G>C (p.Arg63=) variant in GAMT is a synonymous (silent) variant that is not predicted by SpliceAI to impact splicing. In addition, it occurs at a nucleotide that is not conserved as shown by phyloP (score -1.308) (BP4, BP7). To our knowledge, this variant has not been reported among individuals with GAMT deficiency and results of functional studies are unavailable. The highest population minor allele frequency in gnomAD v4.1.0 is 0.0004955 (3/6054) in the Middle Eastern population. This is higher than the ClinGen CCDS VCEP's threshold for PM2_Supporting (<0.0004), and lower than the threshold for BS1 (>0.001). Therefore, no population criteria are met. There is a ClinVar entry for this variant (Variation ID: 288963). In summary, this variant meets the criteria to be classified as likely benign for GAMT deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel (Specifications Version 2.0.0): BP4, BP7. (Classification approved by the ClinGen Cerebral Creatine Deficiency Syndromes Variant Curation Expert Panel on May 20, 2025). -
not specified Benign:1
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Inborn genetic diseases Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Cerebral creatine deficiency syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at